Alamar Biosciences
Alamar Biosciences is a life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. The company leverages its proprietary NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology and the ARGO HT System to detect biomarkers with ultra-high sensitivity, offering more than 10,000-fold improvement in signal-to-noise ratio compared to traditional immunoassay approaches.
Public Company
Alamar Biosciences is publicly traded
IPO'd on April 17, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under ALMR.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Total Funding
$250M
4 rounds
Last Private Valuation
$1.08B
February 26, 2024
Funding
Total raised $250M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-06-2026
Latest Round
Type
IPO
Date
April 17, 2026
Amount
$191.3M
Valuation
$1.08B
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| April 17, 2026 | IPO | $191.3M | $1.08B | |
| February 26, 2024 | Series C | $128M | $1.08B | Sands Capital |
| September 8, 2021 | Series B | $80M | — | Sherpa Healthcare Partners |
Funding by Round
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation Trajectory
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series C
$1.1B
Feb 2024
Alamar Biosciences today
$1.1B
Apr 2026 · latest mark
Alamar Biosciences multiple
1.0x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
Yuling Luo
Founder, Chairman & CEO
Steve Chen
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
SomaLogic
Proteomics company specializing in protein biomarker detection using aptamer technology
Olink Proteomics
Swedish proteomics company providing protein biomarker analysis platforms
Quanterix
Biotech company offering ultra-sensitive protein detection and measurement solutions
Alamar Biosciences Investment FAQ
Alamar Biosciences FAQ
Yes, Alamar Biosciences is publicly traded under the ticker symbol ALMR on the NASDAQ. The company went public in April 17, 2026.
Alamar Biosciences trades under the ticker symbol ALMR on the NASDAQ. It began trading in April 17, 2026.
Alamar Biosciences (ALMR on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ALMR to place an order.
Alamar Biosciences went public in April 17, 2026 via ipo, with an offering valuation of approximately $1.08B. Alamar Biosciences completed its initial public offering on April 17, 2026, pricing 11,250,000 shares at $17.00 per share on the NASDAQ under ticker ALMR. The IPO raised gross proceeds of approximately $191.3 million, with shares opening at $22.60 on first day of trading.
Alamar Biosciences raised $250M across 4 disclosed funding rounds prior to its public listing.
Alamar Biosciences was co-founded by Yuling Luo, and Steve Chen in 2018.
Alamar Biosciences is headquartered in Fremont, CA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.